Developer docs
API playgroundTry for free, no card

Search company profiles

Geneoscopy

Full company profile

uuid00005vh

Namestring
Geneoscopy
Legal namestring
Geneoscopy, Inc.
Websiteurl
geneoscopy.com
Company typeenum
Private
Founded yearint
2015
Short descriptiontext

Geneoscopy is a St. Louis-based molecular diagnostics company that developed ColoSense, the first FDA-approved RNA-based stool test for non-invasive colorectal cancer screening in average-risk adults aged 45 and older, distributed nationwide through Labcorp and reimbursed by Medicare and commercial payors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSt Louis, United States
HQ citystring
St Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
colorectal cancer screening, RNA biomarker diagnostics, stool-based diagnostics, gastrointestinal disease diagnostics, non-invasive cancer screening
Industry3 codes
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Testing Laboratories8734
Product category
Molecular Cancer Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Test Sales - ColoSense
TypeTransaction Fee
Description

Geneoscopy generates revenue through the sale of its FDA-approved ColoSense colorectal cancer screening test. The test is performed at Geneoscopy's CLIA/CAP accredited laboratory in St. Louis. Revenue is derived from reimbursement from Medicare, Medicare Advantage, and commercial payors for eligible screening tests ordered by healthcare providers.

prnewswire.com
2Laboratory Services
TypeTransaction Fee
Description

The company operates its own FDA-approved clinical laboratory to process ColoSense tests. Revenue is generated per test performed, with coverage established through CMS (Medicare) and commercial insurance agreements.

vcaonline.com
3Biopharma Research Partnerships
TypeProfessional Services
Description

Geneoscopy provides biomarker analysis services to biopharma companies conducting clinical trials. The company's RNA extraction platform can be used as clinical trial tools to help reduce costs and accelerate studies for GI therapies.

geneoscopy.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Medicare-covered screening test for eligible beneficiaries
ModelOtherBilling cadencePay-as-you-go
Notes

CMS coverage update in June 2026 expanded access for Medicare and Medicare Advantage beneficiaries. Coverage applies to average-risk adults aged 45-85. Commercial insurance coverage varies by payor.

medicaldevice-network.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1ColoSense
Description

FDA-approved noninvasive multi-target stool RNA (mt-sRNA) colorectal cancer screening test for adults aged 45 and older at average risk for colorectal cancer.

geneoscopy.com
Core offering1 text field

Geneoscopy develops, manufactures, and performs the FDA-approved ColoSense test, a non-invasive multi-target stool RNA (mt-sRNA) screening assay for colorectal cancer and advanced adenomas in average-risk adults aged 45 and older. The company processes samples at its own CLIA/CAP-accredited clinical laboratory in St. Louis, MO, and is extending its proprietary stool-derived eukaryotic RNA (seRNA) biomarker platform into inflammatory bowel disease diagnostics and biopharma research partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • 93% sensitivity for colorectal cancer detection
+8 more records
Product overview1 text field

Geneoscopy operates a platform-based business model centered on its proprietary stool-derived eukaryotic RNA (seRNA) biomarker technology. The company's flagship product is ColoSense, the first FDA-approved RNA-based stool test for colorectal cancer screening in average-risk adults aged 45 and older. The seRNA platform extracts and analyzes human RNA from stool samples to detect biomarkers associated with colorectal neoplasia and inflammatory bowel disease. Geneoscopy is expanding its diagnostic pipeline to address inflammatory bowel disease through partnerships with biopharmaceutical companies, while continuing to advance its core colorectal cancer screening franchise.

Product and service2 records
1ColoSense
CategoryColorectal Cancer Screening Diagnostic Test
Description

FDA-approved noninvasive multi-target stool RNA (mt-sRNA) screening test for colorectal cancer (CRC) and advanced adenomas in average-risk adults aged 45 and older. The first and only FDA-approved stool RNA test for CRC screening, using proprietary RNA biomarkers to detect colorectal neoplasia-associated markers and occult hemoglobin in stool samples. Indicated for adults aged 45-85 at average risk for CRC; covered by Medicare and Medicare Advantage.

2Biopharma Biomarker Research Services
CategoryBiopharma Research Services
Description

Contract biomarker analysis services provided to biopharmaceutical companies conducting clinical trials in gastrointestinal diseases. Geneoscopy's RNA extraction and analysis platform is used as a clinical trial tool to identify immunological markers predicting patient response to therapy, monitor mucosal healing, and reduce required colonoscopies in IBD and other GI therapy trials.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-08
Description

Bio-Rad led Geneoscopy's $105M Series C funding round and provides its QXDx ddPCR technology for use with Geneoscopy's ColoSense test. The partnership combines Geneoscopy's RNA biomarker platform with Bio-Rad's droplet digital PCR instruments, advancing ddPCR as a foundational technology for oncology diagnostics applications.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-12-05
Description

Strategic collaboration to use Geneoscopy's RNA biomarker technology as a precision immunology measure in Adiso's ADS051 Phase 2 IBD trial. Geneoscopy will assess stool-based transcriptome changes to identify immunological markers predicting patient response to therapy, advancing non-invasive diagnostics for IBD treatment monitoring.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-11-14
Description

Multi-year commercial collaboration for nationwide distribution of ColoSense. Labcorp offers Geneoscopy's FDA-approved RNA-based colorectal cancer screening test through its comprehensive laboratory services, enabling healthcare providers to order the test as part of routine screening programs. Test processing occurs at Geneoscopy's facility with samples collected at Labcorp locations.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Exact Sciences markets Cologuard, the dominant noninvasive stool-DNA colorectal cancer screening test. Cologuard is Geneoscopy's most direct competitor in the average-risk CRC screening market and the primary incumbent Geneoscopy must displace to gain share.

TypeDirect peer
Description

Guardant Health's Shield is a blood-based colorectal cancer screening test. As an emerging alternative modality in the same screening market, Shield directly competes for the same at-home screening patient and shares the convenience narrative that drives patient compliance.

TypeDirect peer
Description

Freenome is developing a blood-based multi-omic CRC screening test and represents a next-generation competitor in the noninvasive screening space. Its blood-based approach targets the same patient convenience gap that Geneoscopy's stool RNA test addresses.

TypeBroad incumbent
Description

Labcorp is one of the two largest clinical laboratory services companies in the US and serves as Geneoscopy's nationwide distribution partner for ColoSense. While a partner, Labcorp's broad diagnostic portfolio and incumbent position in CRC screening (including potential competing tests) make it both an enabler and a strategic variable.

TypeBroad incumbent
Description

Quest Diagnostics is a national clinical laboratory giant offering a broad menu of diagnostic services including CRC screening options. As a broad incumbent in the same channel that drives physician test ordering, Quest competes for the same screening volume that ColoSense targets.

6Mainz Biomed
TypeEmerging player
Description

Mainz Biomed is developing ColoAlert, a stool-based CRC screening test with molecular biomarkers. As a smaller European-rooted competitor pursuing the same noninvasive CRC screening opportunity, Mainz Biomed represents an emerging competitive threat particularly in international expansion scenarios.

TypeEmerging player
Description

VolitionRx is developing NuQ blood-based cancer diagnostic tests, including applications in colorectal cancer. Its blood-based approach intersects with the broader noninvasive CRC screening market that Geneoscopy targets with its stool RNA platform.

TypeBroad incumbent
Description

Hologic is a major women's health and diagnostics company that has expanded into oncology diagnostics via the Biotheranostics acquisition. It operates in adjacent cancer diagnostics and employs commercial leadership profiles similar to Geneoscopy's go-to-market motion.

TypeOthers
Description

Bio-Rad is the manufacturer of the QXDx ddPCR system used in the ColoSense workflow and led Geneoscopy's $105M Series C round. While not a direct competitor, Bio-Rad is an enabling technology partner and investor whose strategic interests are tightly linked to Geneoscopy's commercial success.

TypeBroad incumbent
Description

Becton Dickinson is a major diagnostics and life sciences company with a broad portfolio including molecular diagnostics and laboratory instrumentation. It competes in the broader CRC and clinical diagnostics space and represents a potential strategic acquirer of platform diagnostics assets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Geneoscopy

Molecular Cancer Diagnosticsgeneoscopy.com

Geneoscopy is a St. Louis-based molecular diagnostics company that developed ColoSense, the first FDA-approved RNA-based stool test for non-invasive colorectal cancer screening in average-risk adults aged 45 and older, distributed nationwide through Labcorp and reimbursed by Medicare and commercial payors.

Geneoscopy firmographics

Firmographics
Name
Geneoscopy
Legal name
Geneoscopy, Inc.
Website
https://geneoscopy.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Geneoscopy is a St. Louis-based molecular diagnostics company that developed ColoSense, the first FDA-approved RNA-based stool test for non-invasive colorectal cancer screening in average-risk adults aged 45 and older, distributed nationwide through Labcorp and reimbursed by Medicare and commercial payors.
Ownership category
akta.pro rank

Geneoscopy industry classification

Industry
Product category
Molecular Cancer Diagnostics
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing

Keywords

  • Colorectal cancer screening
  • RNA biomarker diagnostics
  • Stool-based diagnostics
  • Gastrointestinal disease diagnostics
  • Non-invasive cancer screening

Where Geneoscopy is headquartered

Location

Headquarters

HQ city
St Louis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Geneoscopy business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Diagnostic Test Sales - ColoSense: Geneoscopy generates revenue through the sale of its FDA-approved ColoSense colorectal cancer screening test. The test is performed at Geneoscopy's CLIA/CAP accredited laboratory in St. Louis. Revenue is derived from reimbursement from Medicare, Medicare Advantage, and commercial payors for eligible screening tests ordered by healthcare providers.
  2. Laboratory Services: The company operates its own FDA-approved clinical laboratory to process ColoSense tests. Revenue is generated per test performed, with coverage established through CMS (Medicare) and commercial insurance agreements.
  3. Biopharma Research Partnerships: Geneoscopy provides biomarker analysis services to biopharma companies conducting clinical trials. The company's RNA extraction platform can be used as clinical trial tools to help reduce costs and accelerate studies for GI therapies.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goMedicare-covered screening test for eligible beneficiaries

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Geneoscopy product offering

Product offering

Core offering

Geneoscopy develops, manufactures, and performs the FDA-approved ColoSense test, a non-invasive multi-target stool RNA (mt-sRNA) screening assay for colorectal cancer and advanced adenomas in average-risk adults aged 45 and older. The company processes samples at its own CLIA/CAP-accredited clinical laboratory in St. Louis, MO, and is extending its proprietary stool-derived eukaryotic RNA (seRNA) biomarker platform into inflammatory bowel disease diagnostics and biopharma research partnerships.

Product overview

Geneoscopy operates a platform-based business model centered on its proprietary stool-derived eukaryotic RNA (seRNA) biomarker technology. The company's flagship product is ColoSense, the first FDA-approved RNA-based stool test for colorectal cancer screening in average-risk adults aged 45 and older. The seRNA platform extracts and analyzes human RNA from stool samples to detect biomarkers associated with colorectal neoplasia and inflammatory bowel disease. Geneoscopy is expanding its diagnostic pipeline to address inflammatory bowel disease through partnerships with biopharmaceutical companies, while continuing to advance its core colorectal cancer screening franchise.

Differentiator

Problem solved

Functional benefit

Brands

  • ColoSense: FDA-approved noninvasive multi-target stool RNA (mt-sRNA) colorectal cancer screening test for adults aged 45 and older at average risk for colorectal cancer.

Products and services

  • ColoSense FDA-approved noninvasive multi-target stool RNA (mt-sRNA) screening test for colorectal cancer (CRC) and advanced adenomas in average-risk adults aged 45 and older. The first and only FDA-approved stool RNA test for CRC screening, using proprietary RNA biomarkers to detect colorectal neoplasia-associated markers and occult hemoglobin in stool samples. Indicated for adults aged 45-85 at average risk for CRC; covered by Medicare and Medicare Advantage.
  • Biopharma Biomarker Research Services Contract biomarker analysis services provided to biopharmaceutical companies conducting clinical trials in gastrointestinal diseases. Geneoscopy's RNA extraction and analysis platform is used as a clinical trial tool to identify immunological markers predicting patient response to therapy, monitor mucosal healing, and reduce required colonoscopies in IBD and other GI therapy trials.

Quantifiable outcome

  • 93% sensitivity for colorectal cancer detection
  • +8 more outcomes

Companies that use Geneoscopy

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Geneoscopy technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature6 records

Geneoscopy partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and major.

  • Bio-Rad LaboratoriescoreTechnology or Integration · 8 January 2025Bio-Rad led Geneoscopy's $105M Series C funding round and provides its QXDx ddPCR technology for use with Geneoscopy's ColoSense test. The partnership combines Geneoscopy's RNA biomarker platform with Bio-Rad's droplet digital PCR instruments, advancing ddPCR as a foundational technology for oncology diagnostics applications.
  • Adiso TherapeuticsmajorStrategic or Co-development Partner · 5 December 2023Strategic collaboration to use Geneoscopy's RNA biomarker technology as a precision immunology measure in Adiso's ADS051 Phase 2 IBD trial. Geneoscopy will assess stool-based transcriptome changes to identify immunological markers predicting patient response to therapy, advancing non-invasive diagnostics for IBD treatment monitoring.
  • LabcorpcoreChannel Partner/ Reseller/ Distributor · 14 November 2023Multi-year commercial collaboration for nationwide distribution of ColoSense. Labcorp offers Geneoscopy's FDA-approved RNA-based colorectal cancer screening test through its comprehensive laboratory services, enabling healthcare providers to order the test as part of routine screening programs. Test processing occurs at Geneoscopy's facility with samples collected at Labcorp locations.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Geneoscopy competitors and assessment

Company assessment

Direct peers

  • Exact Sciences: Exact Sciences markets Cologuard, the dominant noninvasive stool-DNA colorectal cancer screening test. Cologuard is Geneoscopy's most direct competitor in the average-risk CRC screening market and the primary incumbent Geneoscopy must displace to gain share.
  • Guardant Health: Guardant Health's Shield is a blood-based colorectal cancer screening test. As an emerging alternative modality in the same screening market, Shield directly competes for the same at-home screening patient and shares the convenience narrative that drives patient compliance.
  • Freenome: Freenome is developing a blood-based multi-omic CRC screening test and represents a next-generation competitor in the noninvasive screening space. Its blood-based approach targets the same patient convenience gap that Geneoscopy's stool RNA test addresses.

Broad incumbents

  • Labcorp: Labcorp is one of the two largest clinical laboratory services companies in the US and serves as Geneoscopy's nationwide distribution partner for ColoSense. While a partner, Labcorp's broad diagnostic portfolio and incumbent position in CRC screening (including potential competing tests) make it both an enabler and a strategic variable.
  • Quest Diagnostics: Quest Diagnostics is a national clinical laboratory giant offering a broad menu of diagnostic services including CRC screening options. As a broad incumbent in the same channel that drives physician test ordering, Quest competes for the same screening volume that ColoSense targets.
  • Hologic: Hologic is a major women's health and diagnostics company that has expanded into oncology diagnostics via the Biotheranostics acquisition. It operates in adjacent cancer diagnostics and employs commercial leadership profiles similar to Geneoscopy's go-to-market motion.
  • Becton Dickinson: Becton Dickinson is a major diagnostics and life sciences company with a broad portfolio including molecular diagnostics and laboratory instrumentation. It competes in the broader CRC and clinical diagnostics space and represents a potential strategic acquirer of platform diagnostics assets.

Emerging players

  • Mainz Biomed: Mainz Biomed is developing ColoAlert, a stool-based CRC screening test with molecular biomarkers. As a smaller European-rooted competitor pursuing the same noninvasive CRC screening opportunity, Mainz Biomed represents an emerging competitive threat particularly in international expansion scenarios.
  • VolitionRx: VolitionRx is developing NuQ blood-based cancer diagnostic tests, including applications in colorectal cancer. Its blood-based approach intersects with the broader noninvasive CRC screening market that Geneoscopy targets with its stool RNA platform.

Others

  • Bio-Rad Laboratories: Bio-Rad is the manufacturer of the QXDx ddPCR system used in the ColoSense workflow and led Geneoscopy's $105M Series C round. While not a direct competitor, Bio-Rad is an enabling technology partner and investor whose strategic interests are tightly linked to Geneoscopy's commercial success.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Geneoscopy social profiles

Digital presence

Geneoscopy compliance and trust

Trust signal

Compliance4 records

Geneoscopy financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Geneoscopy leadership team

Management profile

Number of profiles

Profiles10 records

Geneoscopy funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Geneoscopy M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Geneoscopy

What does Geneoscopy do?

Geneoscopy develops, manufactures, and performs the FDA-approved ColoSense test, a non-invasive multi-target stool RNA (mt-sRNA) screening assay for colorectal cancer and advanced adenomas in average-risk adults aged 45 and older. The company processes samples at its own CLIA/CAP-accredited clinical laboratory in St. Louis, MO, and is extending its proprietary stool-derived eukaryotic RNA (seRNA) biomarker platform into inflammatory bowel disease diagnostics and biopharma research partnerships.

Is Geneoscopy a public or private company?

Geneoscopy is a private company. It is classified as venture growth investor backed and is currently operating.

When was Geneoscopy founded?

Geneoscopy was founded in 2015. It employs 51 to 100 people.

Where is Geneoscopy based?

Geneoscopy is headquartered in St Louis, United States, in the North America region.

How does Geneoscopy make money?

Three revenue lines are on record. Diagnostic Test Sales - ColoSense is the primary driver. The others are laboratory Services and biopharma Research Partnerships.

Who are Geneoscopy's main competitors?

Direct peers on record are Exact Sciences, Guardant Health and Freenome. Broad incumbents are Labcorp, Quest Diagnostics, Hologic and Becton Dickinson. Emerging players are Mainz Biomed and VolitionRx. Bio-Rad Laboratories is listed as an others.

Does Geneoscopy have an API?

No public API is recorded for Geneoscopy.

What industry is Geneoscopy in?

Geneoscopy's product category is Molecular Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
OncLiveFDA Approves Noninvasive Stool RNA Screening Test for CRCThe FDA has approved ColoSense, a noninvasive multi-target stool RNA screening test developed by Geneoscopy, for use in adults aged 45 and older at average risk of colorectal cancer. Clinical data from the phase 3 CRC-PREVENT trial demonstrated that the test exhibits 93% sensitivity for detecting colorectal cancer and 100% sensitivity for stage I disease. This regulatory milestone provides a new diagnostic option aimed at improving early detection rates and patient outcomes.OncLiveNCCN Adds 2 Tests to CRC Screening GuidelinesThe National Comprehensive Cancer Network (NCCN) has updated its colorectal cancer screening guidelines to include the ColoSense stool RNA test and the Shield blood test. Both tests are recommended for average-risk adults aged 45 and older, with ColoSense developed by Geneoscopy and Shield developed by Guardant Health.Medical Device and Diagnostic industryGeneoscopy Prepares Launch of FDA-approved At-home RNA Colorectal Cancer Screening TestGeneoscopy is preparing to launch Colosense, its FDA-approved at-home RNA-based colorectal cancer screening test, utilizing $105 million in Series C funding secured in 2025. The company aims to secure coverage from the Centers for Medicare and Medicaid Services (CMS) and meet quality metrics for guideline recommendations while partnering with Labcorp for commercial distribution. This launch positions Geneoscopy in direct competition with Exact Sciences' Cologuard, as it seeks to establish RNA technology as a superior diagnostic alternative for gastrointestinal conditions.Packaging DigestNew At-Home Colorectal Cancer Screening Test Touts Ease of UseGeneoscopy has closed a $105 million Series C funding round to commercialize Colosense, its FDA-approved at-home stool RNA test for colorectal cancer screening. The company is partnering with Labcorp for commercial launch and distribution while utilizing Bio-Rad Laboratories' technology for the diagnostic platform.AsuDiagnostics enters its ‘coming of age’ moment with patients at the centerArizona State University's College of Health Solutions and the Personalized Medicine Coalition hosted a roundtable in Washington, D.C., bringing together industry, academic, and government leaders to discuss the future of medical diagnostics, highlighting how COVID-19 normalized at-home testing. Panelists emphasized emerging patient-centric tools, AI-assisted interpretation of lab results, and new blood-based cancer screening tests from companies like Mercy BioAnalytics, Abbott Cancer Diagnostics, GRAIL, and Geneoscopy that can detect cancers earlier when treatment is more effective. Industry leaders stressed that while innovation is advancing rapidly, transparency about test limitations and clear patient communication will be critical to realizing the public health benefits of these new diagnostic technologies.In VivoGeneoscopy RNA-Based Colorectal Cancer Test Now Available Nationwide Through LabcorpLabcorp has announced the nationwide availability of Geneoscopy's ColoSense at-home colorectal cancer screening test across the US, marking the first FDA-approved at-home test to use RNA technology to detect biomarkers associated with colorectal cancer and precancerous changes. The test addresses a growing health concern as colorectal cancer rates rise, particularly among younger adults. Geneoscopy, a St. Louis-based life sciences company, developed the test in partnership with Labcorp for distribution.BCC ResearchWhat If Cancer Detection Became as Simple as a Blood Test?AI technologies including digital pathology, liquid biopsy tests, and deep learning algorithms are reaching a tipping point for making early cancer detection more accessible, with over 2 million Americans diagnosed annually. Major investment activity is accelerating the transformation: Geneoscopy raised $105 million for AI-enabled colorectal screening, while Abbott announced a $23 billion acquisition of Exact Sciences to enter the cancer diagnostics market. The FDA approved 223 AI-enabled medical devices in 2023, signaling regulatory support for the sector's growth.BioSpaceCMS Grants Medicare Coverage for ColoSense®, Expanding Access to Simplified Noninvasive Colorectal Cancer ScreeningCMS approved coverage for ColoSense, a stool-based colorectal cancer screening test, giving Medicare's 65 million beneficiaries access to the first FDA-approved stool-RNA test. The test is 93% sensitive for CRC and 45% for advanced adenomas, with 100% sensitivity for stage I cancer. A partnership with Labcorp will expand access.Business Wire BlogCMS Grants Medicare Coverage for ColoSense®, Expanding Access to Simplified Noninvasive Colorectal Cancer ScreeningThe Centers for Medicare & Medicaid Services (CMS) has approved coverage for ColoSense, a stool-based colorectal cancer screening test developed by Geneoscopy, under the National Coverage Determination. This approval provides approximately 65 million Medicare beneficiaries with access to the FDA-approved, high-sensitivity RNA test, which simplifies sample collection by eliminating the need for stool manipulation. The decision establishes a forward-thinking framework that supports future innovations in non-invasive diagnostic testing.Business Wire BlogGeneoscopy's ColoSense® Test Included as a Preferred Option in the American Cancer Society Colorectal Cancer Screening Guidelines UpdateGeneoscopy announced that the American Cancer Society updated its colorectal cancer screening guidelines to include ColoSense, marking the first time a noninvasive RNA-based test has been added to ACS guidelines for average-risk adults aged 45 and older. The test, which demonstrated 93% sensitivity for colorectal cancer and 100% sensitivity for stage I cancer detection in the CRC-PREVENT trial, is also included in NCCN guidelines and was FDA-approved in May 2024. CMS has proposed coverage that would make ColoSense accessible to 65 million Medicare beneficiaries, with a final decision expected June 8, 2026, while a strategic collaboration with Labcorp aims to further expand provider and patient access.